SLC5A2 and atrial fibrillation: It is important to note that female patients typically develop HF at an older age and more frequently present with diastolic dysfunction, whereas male patients tend to develop HF with systolic dysfunction [21]. The DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) and EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) studies analyzed the relationship between HF, AF, and the use of SGLT2 inhibitors.